Modulation of the unfolded protein response impedes tumor cell adaptation to proteotoxic stress: a PERK for hepatocellular carcinoma therapy

Hepatol Int. 2014 Oct 1;9(1):93-104. doi: 10.1007/s12072-014-9582-0. eCollection 2015 Jan.

Abstract

Background: Functional disturbances of the endoplasmic reticulum (ER) lead to activation of the unfolded protein response (UPR), which is involved in the consecutive steps of carcinogenesis. In human hepatocellular carcinoma (HCC), the UPR is shown to be activated; however, little is known about the UPR kinetics and effects of UPR modulation in HCC.

Methods: We sequentially monitored the UPR over time in an orthotopic mouse model for HCC and explored the effects of UPR modulation on cell viability and proliferation in vitro and in the mouse model.

Results: The expression of ER-resident chaperones peaked during tumor initiation and increased further during tumor progression, predominantly within the nodules. A peak in Ire1 signaling was observed during tumor initiation. The Perk pathway was activated during tumor progression, and the proapoptotic target Chop was upregulated from week 5 and continued to rise, especially in the tumors. The Atf6 pathway was modestly activated only after tumor initiation. Consistent with the UPR activation, electron microscopy demonstrated ER expansion and reorganization in HCC cells in vivo. Strikingly, under ER stress or hypoxia, the Perk inhibitor and not the Ire1 inhibitor reduced cell viability and proliferation via escalating proteotoxic stress in vitro. Notably, the Perk inhibitor significantly decreased tumor burden in the mouse model.

Conclusion: We provide the first evaluation of the UPR dynamics in a long-term cancer model and identified a small molecule inhibitor of Perk as a promising strategy for HCC therapy.

Keywords: Endoplasmic reticulum; HepG2 cells; Inositol-requiring enzyme-1; Liver neoplasm; PERK kinase; Stress.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Activating Transcription Factor 6 / genetics
  • Adaptation, Physiological / drug effects
  • Animals
  • Carcinoma, Hepatocellular / chemistry
  • Carcinoma, Hepatocellular / drug therapy
  • Carcinoma, Hepatocellular / metabolism*
  • Carcinoma, Hepatocellular / ultrastructure
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • Cell Transformation, Neoplastic / metabolism*
  • Endoplasmic Reticulum
  • Endoplasmic Reticulum Chaperone BiP
  • HSP40 Heat-Shock Proteins / genetics
  • Heat-Shock Proteins / genetics
  • Hep G2 Cells
  • Humans
  • Liver Neoplasms, Experimental / chemistry
  • Liver Neoplasms, Experimental / drug therapy
  • Liver Neoplasms, Experimental / metabolism*
  • Liver Neoplasms, Experimental / ultrastructure
  • Male
  • Membrane Glycoproteins / genetics
  • Membrane Proteins / antagonists & inhibitors
  • Membrane Proteins / genetics
  • Mice
  • Oxidative Stress
  • Phosphorylation / drug effects
  • Protein Kinase Inhibitors / pharmacology*
  • Protein Kinase Inhibitors / therapeutic use
  • Protein Serine-Threonine Kinases / antagonists & inhibitors
  • Protein Serine-Threonine Kinases / genetics
  • RNA, Messenger / analysis
  • Signal Transduction
  • Transcription Factor CHOP / analysis
  • Transcription Factor CHOP / genetics
  • Tunicamycin / pharmacology
  • Unfolded Protein Response* / drug effects
  • eIF-2 Kinase / antagonists & inhibitors
  • eIF-2 Kinase / metabolism*

Substances

  • Activating Transcription Factor 6
  • Atf6 protein, mouse
  • Dnajc3 protein, mouse
  • Endoplasmic Reticulum Chaperone BiP
  • HSP40 Heat-Shock Proteins
  • Heat-Shock Proteins
  • Membrane Glycoproteins
  • Membrane Proteins
  • Protein Kinase Inhibitors
  • RNA, Messenger
  • endoplasmin
  • Tunicamycin
  • Transcription Factor CHOP
  • Ern2 protein, mouse
  • PERK kinase
  • Protein Serine-Threonine Kinases
  • eIF-2 Kinase